Bio-Rad Laboratories (STU:BUWA) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BUWA Bio-Rad Laboratories Inc STU:BUWA
71 GF Score
Price €282.00
GF Value €274.29
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:BUWA vs GKOS, BRKR, GMED: Short Interest Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories Short Interest vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Short Interest distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Short Interest falls into.


STU:BUWA
71GF Score
Bio-Rad Laboratories Inc STU:BUWA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bio-Rad Laboratories (STU:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of €282.00 is trading 2.8% above its estimated GF Value™ of €274.29. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for STU:BUWA:

  • Short Interest:
  • GF Value™: €274.29 vs. price of €282.00 (2.8% above fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the STU:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Other Exchanges BIO.B:USABIO:USA
Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score

Get the complete analysis for STU:BUWA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€282.00
Price
€274.29
GF Value